IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Amphastar Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Amphastar Pharmaceuticals, Inc. ("Amphastar" or the "Company") AMPH concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Amphastar shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

Armstrong Pharmaceuticals, Inc. ("Armstrong"), a subsidiary company of Amphastar, received notice from the U.S. Food and Drug Administration ("FDA") that Armstrong's New Drug Application for Primatene Mist, used as an epinephrine inhalation aerosol product, was not approved.

The FDA found issues with the product's packaging and label. The FDA further encouraged Armstrong to conduct another Human Factor validation study to measure consumers' ability to independently use the product.

When this information was disclosed to the public, Amphastar stock fell in value, causing investors serious harm.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161228005349/en/